Stockholm, October 24, 2012 – InDex Pharmaceuticals today announced that it has been granted a
Japanese patent by the Japan Patent Office (JPO). The patent provides protection for the use of
Kappaproct® and other DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-
resistant inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, psoriasis,
asthma, emphysema, and chronic obstructive pulmonary disease.
The patent, entitled “Immunostimulatory Method” covers the use of a broad range of oligonucleotides
for the treatment of steroid resistance in patients afflicted with inflammatory conditions. It provides an
exclusivity period until at least 2026, with the possibility of up to 5 years of patent term extension after
market approval. InDex Pharmaceuticals already holds patent protection for Kappaproct for the
treatment of steroid-resistant inflammatory diseases in both Europe and the US.
“We are very pleased with the granting of this key patent by the Japanese Patent Office, which further
confirms Kappaproct is a unique and innovative asset for treatment-resistant inflammation,” said Jesper
Wiklund, CEO of InDex Pharmaceuticals. “This newly granted patent is an important value driver for
InDex since we now have exclusivity for Kappaproct in Japan beyond 2026. Moreover, it further
strengthens our intellectual property estate for our technology platform.”
InDex Pharmaceuticals develops DIMS compounds - synthetic oligonucleotides that function as
immunomodulatory agents by targeting the Toll-like receptor 9 (TLR9). The company’s most advanced
DIMS product candidate, Kappaproct, is currently in a phase III study in Europe for the treatment of
chronic, active, treatment-refractory ulcerative colitis.
Kappaproct is a single-strand, DNA-based synthetic oligonucleotide. It functions as an immuno-
modulatory agent by targeting TLR9. In clinical trials, Kappaproct has shown positive effects in the
treatment of severe ulcerative colitis patients. A European multicenter Phase III study, COLLECT, is
currently being conducted to evaluate the efficacy and safety of Kappaproct for the treatment of severe
ulcerative colitis patients not responding to available therapy. More information about the ongoing study
can be found on clinicaltrials.gov with the ClinicalTrials.gov Identifier NCT01493960. Kappaproct has
received orphan drug designation in Europe.
About InDex Pharmaceuticals
InDex Pharmaceuticals is a biopharmaceutical company focusing on the discovery and development of
immunology-based treatments exclusively addressing disease states with a high unmet medical need.
InDex Pharmaceuticals is also dedicated to personalized medicine and is developing companion
diagnostics that will allow for the selection of only those patients likely to respond to a treatment. In
2009, InDex Pharmaceuticals launched the diagnostic test DiBiCol® in Sweden. DiBiCol differentiates
between ulcerative colitis and Crohn’s disease, the two major forms of inflammatory bowel disease.
InDex Pharmaceuticals was founded in 2000 and is located in Stockholm, Sweden.
For additional information about Kappaproct and InDex Pharmaceuticals please visit
Contact InDex Pharmaceuticals:
Jesper Wiklund, CEO
Tel: +46 8 508 847 35/ +46 (0)733 59 05 53
Dr. Ludger Wess or Ines-Regina Buth
Tel.: +49 (0)40 88 16 59 64 / +49 (0)30 2363 2768